The latest price target for ArriVent BioPharma (NASDAQ:AVBP) was reported by Citigroup on May 13, 2026. The analyst firm set a price target for $43.00 expecting AVBP to rise to within 12 months (a possible 59.02% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for ArriVent BioPharma (NASDAQ:AVBP) was provided by Citigroup, and ArriVent BioPharma maintained their buy rating.

There is no last upgrade for ArriVent BioPharma

There is no last downgrade for ArriVent BioPharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ArriVent BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ArriVent BioPharma was filed on May 13, 2026 so you should expect the next rating to be made available sometime around May 13, 2027.

While ratings are subjective and will change, the latest ArriVent BioPharma (AVBP) rating was a maintained with a price target of $45.00 to $43.00. The current price ArriVent BioPharma (AVBP) is trading at is $27.04, which is out of the analyst’s predicted range.